Article Preserved Ejection Fraction Quality of Life 
American College of Cardiology
NOVEMBER 16, 2024
In patients with obesity and heart failure with preserved ejection fraction (HFpEF), weekly treatment with tirzepatide over approximately two years reduced the risk of worsening heart failure events, based on findings from the SUMMIT trial.
HeartRhythm
SEPTEMBER 4, 2024
Heart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) are comorbid conditions that are increasingly prevalent and have a high socioeconomic burden. This article discusses their shared pathophysiology, focusing on the triad of hypertension, obesity, and aging.We
Circulation
SEPTEMBER 2, 2024
Circulation, Volume 150, Issue 10 , Page e224-e225, September 3, 2024.
European Journal of Heart Failure
DECEMBER 7, 2023
Increasing severity of obesity is associated with multiple characteristics that may contribute to the development or worsening of heart failure (HF) with preserved ejection fraction (HFpEF). Overall, 60.9% of patients had BMI ≥30 kg/m 2.
European Journal of Heart Failure
DECEMBER 20, 2023
Abstract Introduction Emerging evidence suggests a beneficial effect of higher heart rates in some patients with heart failure with preserved ejection fraction (HFpEF). This article is protected by copyright. All rights reserved.
European Journal of Heart Failure
DECEMBER 13, 2023
BMI, body mass index; CI, confidence interval; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide. ABSTRACT Aim Chronic obstructive pulmonary disease (COPD) is common in heart failure with a mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) and is associated with worse outcomes.
Expert insights. Personalized for you.
75 
Let's personalize your content